Results 151 to 160 of about 284,051 (203)

Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

J Atheroscler Thromb
Shishikura D, Harada-Shiba M, Michikura M, Fujioka S, Fujisaka T, Morita H, Kanzaki Y, Hoshiga M.   +7 more
europepmc   +1 more source

Biochemical and Anthropometric Outcomes in Paediatric Patients with Heterozygous Familial Hypercholesterolemia after COVID-19 Pandemic Lockdowns: An Exploratory Analysis. [PDF]

Nutrients
Peres M, Moreira-Rosário A, Padeira G, Gaspar Silva P, Correia C, Nunes A, Garcia E, Faria A, Teixeira D, Calhau C, Pereira-da-Silva L, Ferreira AC, Rocha JC.   +12 more
europepmc   +1 more source

Failure of lipid control by PCSK9 inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report. [PDF]

Clin Case Rep
Zhang Z, Yang R, Zhu J, Yang X, Luo H, Wang H, Luo X.   +6 more
europepmc   +1 more source

Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA Pediatr
Santos RD, Wiegman A, Caprio S, Cariou B, Averna M, Poulouin Y, Scemama M, Manvelian G, Garon G, Daniels S.   +9 more
europepmc   +1 more source

† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia

Journal of Clinical Lipidology
Andy Hsieh, Stephen Nicholls, Adam J Nelson, Marc Ditmarsch, John J.P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie Neild, Douglas Kling, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael H. Davidson   +19 more
openaire   +1 more source

Lifestyle intervention in familial hypercholesterolemia

, 2017
Tan, KCB
core  

Pediatric implications of heterozygous familial hypercholesterolemia

, 2003
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Heterozygous familial hypercholesterolemia: prevalence and control rates

Expert Review of Endocrinology and Metabolism, 2021
Introduction: Heterozygous familial hypercholesterolemia (heFH) is associated with a very high risk for cardiovascular events. Treatment with potent statins substantially reduces cardiovascular morbidity in these patients. Moreover, combination therapy with statins plus ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ...
Konstantinos Tziomalos, Georgios Polychronopoulos   +1 more
exaly   +3 more sources

Severe xanthomatosis in heterozygous familial hypercholesterolemia

Journal of Clinical Lipidology, 2018
Familial hypercholesterolemia is a genetic lipoprotein disorder characterized by elevated plasma low-density lipoprotein cholesterol level, (tendinous xanthomas, xanthelasmas, and premature arcus corneus) and early onset atherosclerotic cardiovascular disease. Familial hypercholesterolemia is caused by mutations in the low-density lipoprotein receptor,
Sumayah Aljenedil, Isabelle Ruel
exaly   +3 more sources